GlaxoSmithKline (GB:GSK) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
GlaxoSmithKline has announced encouraging phase II results for its mRNA seasonal influenza vaccine, showing strong immune responses against influenza A and B strains in adults. These findings confirm the vaccine’s safety and efficacy, paving the way for phase III clinical trials. The company is also expanding its vaccine development efforts through a new licensing agreement with CureVac and investments in mRNA technology.
For further insights into GB:GSK stock, check out TipRanks’ Stock Analysis page.
